Monday 10 October 2005
The Institute of Cancer Research is delighted to announce the appointment of Lord Ryder of Wensum as its new Chairman. Lord Ryder succeeds Lord Faringdon who stepped down at the end of September after 25 years' association with The Institute.
Prior to joining The Institute Lord Ryder was MP for Mid-Norfolk between 1983 and 1997. He held several ministerial positions including Economic Secretary to HM Treasury and Government Chief Whip. He was also Chairman of Eastern Counties Radio, Vice Chairman of the BBC and is a crossbencher in the House of Lords.
“We are delighted to welcome Lord Ryder as the new Chairman of The Institute,” said Professor Peter Rigby, Chief Executive of The Institute of Cancer Research. “Lord Ryder brings to The Institute many years of invaluable experience from his previous career and the passion to drive our ongoing fight against cancer.”
Lord Ryder, Chairman of The Institute of Cancer Research said, “I look forward to starting my new role as Chairman of such a prestigious cancer research organisation. With so many world-class scientists at The Institute our work is truly at the forefront of global cancer research.”
- ends -
For further information and interviews please contact:
The Institute of Cancer Research Press Office:
020 7153 5359
[email protected]
Notes to Editors:
- The Institute of Cancer Research is Europe’s leading cancer research centre with expert scientists working on cutting edge research. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis, treatment and care. Website at: www.icr.ac.uk
- The Institute works in a unique partnership with The Royal Marsden NHS Foundation Trust, forming the largest comprehensive cancer centre in Europe. This relationship enables close daily contact with those on the frontline in the fight against cancer - the clinicians, the carers and most importantly, the patients.
- The Institute is a charity that relies on voluntary income. The Institute is one of the world’s most cost-effective major cancer research organisations with over 90p in every £ directly supporting research.